View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financ...

Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update. Fourth Quarter and Recent Highlights The pivotal STRIDE study of mavodelpar in adult patients with primary mitochond...

 PRESS RELEASE

Hudbay Provides Annual Reserve and Resource Update and Production Outl...

Hudbay Provides Annual Reserve and Resource Update and Production Outlook Consolidated copper production is expected to average 153,000i tonnes per year over the next three years, representing a 16% increase from 2023 and demonstrating Hudbay’s strong and stable operating portfolio with three long-life operations in tier-one mining jurisdictions in the Americas. Strong complementary gold exposure with consolidated gold production expected to average 272,500i ounces per year over the next three years, reflecting strong production in Manitoba and a contribution from Pampacancha high grade gol...

 PRESS RELEASE

Perspective Therapeutics Provides Recent Business Highlights and Repor...

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.  “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therap...

 PRESS RELEASE

Quipt Home Medical Announces Voting Results from Its Annual General an...

Quipt Home Medical Announces Voting Results from Its Annual General and Special Meeting of Shareholders CINCINNATI, March 28, 2024 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the voting results from its annual general and special meeting of shareholders held on March 27, 2024 (the “Meeting”) in Wilder, Kentucky. The total number of shares represented in person or by proxy at the Meeting was 25,432,699, representing 60.4% of the total issued an...

 PRESS RELEASE

Avicanna anuncia el lanzamiento en Canadá de una formulación de su pro...

Avicanna anuncia el lanzamiento en Canadá de una formulación de su propiedad con un 10% de CBD (sin THC) La formulación oral con un 10% de CBD (sin THC) se comercializa como RHO Phyto Micro Drop 100 en Canadá. RHO Phyto Micro Drop 100 está disponible exclusivamente en MyMedi.ca. TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Avicanna Inc. ("Avicanna" o la "Compañía") (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), una compañía biofarmacéutica centrada en el desarrollo, fabricación y comercialización de productos basados en cannabinoides derivados de plantas, se complace en anunciar el lanzamiento e...

 PRESS RELEASE

Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs...

Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform Study to assess new camptothecin-peptide conjugates for the treatment of sortilin-positive colorectal cancers Separate data to highlight activity of sudocetaxel zendusortide (TH1902) to trigger the cGAS/STING pathway potentiate and anti-PD-L1 immunotherapy tumor cell killing MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and com...

 PRESS RELEASE

Theratechnologies présentera au congrès de l’AACR des données préclini...

Theratechnologies présentera au congrès de l’AACR des données précliniques sur plusieurs conjugués peptide-médicament illustrant le potentiel de sa plateforme technologique SORT1+(MC) Une étude permettra d’évaluer de nouveaux conjugués camptothécine-peptide pour le traitement des cancers colorectaux exprimant la sortilineDes données distinctes mettent en évidence l’activité du sudocétaxel zendusortide (TH1902) pour activer la voie cGAS-STING et potentialiser la destruction de cellules tumorales par immunothérapie anti-PD-L1 MONTRÉAL, 28 mars 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc...

 PRESS RELEASE

Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financ...

Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results 2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth quarter and full-year 2023 to $3.5 million and $15.9 million, respectively Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused ...

 PRESS RELEASE

Jiayin Group Inc. Reports Fourth Quarter and Fiscal Year 2023 Unaudite...

Jiayin Group Inc. Reports Fourth Quarter and Fiscal Year 2023 Unaudited Financial Results  -- Full Year Revenue Grew 67.1% to RMB5,467 million -- -- Full Year Net Income Grew 9.9% to RMB1,298 million -- SHANGHAI, China, March 28, 2024 (GLOBE NEWSWIRE) -- Jiayin Group Inc. (“Jiayin” or the “Company”) (NASDAQ: JFIN), a leading fintech platform in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2023. Fourth Quarter 2023 Operational and Financial Highlights: Loan facilitation volume1 was RMB20.1 billion (US$2.8 bil...

 PRESS RELEASE

First-Time Buyers Must Make $76,000 to Afford the Typical U.S. Starter...

SEATTLE--(BUSINESS WIRE)-- (NASDAQ: RDFN) — Homebuyers must earn $75,849 annually to afford the typical U.S. starter home as of February, up 8.2% ($5,767) from a year earlier, according to a new from Redfin (), the technology-powered real estate brokerage. The monthly housing payment for the typical U.S. starter home was $1,896 in February, also up 8.2% from a year earlier. The income necessary to buy starter homes is increasing from a year ago due to rising prices and mortgage rates: The typical starter home sold for $240,000 in February, up 3.4% year over year, and the average 30-year fix...

 PRESS RELEASE

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2...

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call Call Scheduled for Today, Thursday, March 28, 2024 at 5:00 pm ET LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults)), today announced it plans to release its f...

 PRESS RELEASE

Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psyche...

Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference Optimi CEO Bill Ciprick to speak on the future of GMP psychedelic manufacturing VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading Health Canada licensed psychedelics pharmaceutical manufacturer, specializing in controlled substances such as natural psilocybin and MDMA, proudly announces its role as a Presenting Sponsor at the highly anticipated 4th Annual Psychedelic Therapeutics and Dr...

 PRESS RELEASE

AGF Investments Announces Proposed Termination of AGF Global Opportuni...

AGF Investments Announces Proposed Termination of AGF Global Opportunities Bond ETF, AGF Systematic Canadian Equity ETF and AGF Systematic Emerging Markets Equity ETF TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- AGF Investments Inc. (AGF Investments) (TSX:AGF.B) today announced the proposed termination of AGF Global Opportunities Bond ETF (ticker: AGLB), AGF Systematic Canadian Equity ETF (ticker: QCD) and AGF Systematic Emerging Markets Equity ETF (ticker: QEM) (each an “AGF Investments ETF” and collectively, the “AGF Investments ETFs”) effective at the close of business on or about May 2...

 PRESS RELEASE

Placements AGF annonce une proposition de clôture visant le FNB Obliga...

Placements AGF annonce une proposition de clôture visant le FNB Obligations Occasions mondiales AGF, le FNB Actions canadiennes  ̶ Approche systématique AGF et le FNB Actions des marchés émergents – Approche systématique AGF TORONTO, 28 mars 2024 (GLOBE NEWSWIRE) -- Placements AGF Inc. (« Placements AGF ») (TSX:AGF.B) a annoncé aujourd’hui une proposition de clôture visant le FNB Obligations Occasions mondiales AGF (symbole : AGLB), le FNB Actions canadiennes – Approche systématique AGF (symbole : QCD) et le FNB Actions des marchés émergents – Approche systématique AGF (symbole : QEM) (ch...

Moody's upgrades InFinBank's long-term deposit ratings to B1 and chang...

Moody's Ratings (Moody's) has today upgraded InFinBank's (IFB) long-term local and foreign currency bank deposit ratings to B1 from B2 and changed the outlook on these ratings to stable from positive. Concurrently, Moody's upgraded the bank's Baseline Credit Assessment (BCA) and Adjusted BCA to b1 f...

SaveLend Group AB: 2 directors

Two Directors at SaveLend Group AB bought/maiden bought 56,646 shares at between 3.720SEK and 3.767SEK. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...

 PRESS RELEASE

Designated person notification

Designated person notification 28 March 2024, 12:15 CET With reference to Article 19(3) of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulations), ArcelorMittal announces that a notification of share transaction by a Designated Person (i.e. Directors or Executive Officers) is available in the Luxembourg Stock Exchange’s electronic database OAM on and on ArcelorMittal’s web site under Investors > Share Transactions by Management: ENDS About ArcelorMittal ArcelorMittal is one of the world’s leading integrate...

 PRESS RELEASE

Pluri’s Business Verticals Gain Traction in Global Markets; Leadership...

Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences Pluri’s business verticals leverage Company’s world-leading 3D cell expansion know-how, IP, and manufacturing facility to drive revenue and bring innovative cell-based solutions to numerous industries HAIFA, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, today announced leadership from its business ...

Felix Fischer
  • Felix Fischer

Lucror Analytics - Morning Views Latam

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar. To request full and unrestricted access to Lucror’s research and analytics platform, please visit

Daud Bhatti
  • Daud Bhatti

Nasdaq 100 (NQ) Potential Support Area

  March 28, 2024 By  Short Term Elliott Wave view in Nasdaq 100 (NQ) suggests that pullback to 18011.3 ended wave 4. The Index has turned higher in wave 5. Internal subdivision of wave 5 is unfolding as a diagonal. Up from wave 4, wave (i) ended at 18106.75 and wave (ii) ended at 18044. Wave (iii) higher ended at 18289.25 and wave (iv) ended at 18263.25. Final leg wave (v) ended at 18381 which completed wave ((i)). Pullback in wave ((ii)) ended at 18053.25 as a zigzag. The Index then res...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch